25 results
8-K
EX-99.1
ARAV
Aravive Inc
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
is a platform that guarantees that the European spirit and culture is incorporated into the medical progress in gynaecological oncology, and that all European
S-4
EX-10.6
ARAV
Aravive Inc
3 Aug 18
Registration of securities issued in business combination transactions
5:26pm
in connection with the Manufacture of GMP Batches.
1.48“Raw Materials” shall mean starting materials, cell lines, reagents, cell culture media
10-K
b83162d 6t
6 Mar 15
Annual report
12:00am
424B4
9ju1rvnz
22 Jan 15
Prospectus supplement with pricing info
12:00am